Drug Profile
ARI 3037MO
Alternative Names: ARI-3037MOLatest Information Update: 14 Jun 2018
Price :
$50
*
At a glance
- Originator Arisaph Pharmaceuticals
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias; Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 14 Jun 2018 No recent reports on development identified - Phase-II for Dyslipidaemias in USA (PO)
- 14 Jun 2018 No recent reports on development identified - Phase-II for Hypertriglyceridaemia in USA (PO)
- 14 Jun 2018 No recent reports on development identified - Phase-II for Non-alcoholic fatty liver disease in USA (PO)